Home | Research & Innovation | Innovation | Portfolio/Technological Offer

Outstanding Patents

PI3K obesity/ EIM. Use of PI3K inhibitors for the treatment of obesity, steatosis and ageing
MCXs PI3K-PIM / Inflection. Macrocyclic compounds as protein kinase inhibitors
ATR/Merck. Chemical entities

Monoclonal Antibodies

As well as suggesting new methods of classification and diagnosis, understanding the role of Monoclonal Antibodies is essential in comprehending the biology of tumour cells. The CNIO’s Monoclonal Antibodies unit produces high quality, novel antibodies. It also characterizes them, thereby allowing researchers to have dozens of reliable, validated reagents at their disposal.

Each year the CNIO publishes an in-depth catalogue highlighting the more than 80 top drawer antibodies against humans and other species currently in production.

For further information on our patents and technology offerings, contact: technologytransfer@cnio.es